An inaugural edition of the mailbag. Questions are block formatted. Allons-y…
"I read with interest your article. Everybody has the right to his opinion, but coming from someone with your background, who worked for the mayo clinic for years in the field of myocardial remodeling, your opinion carries particular weight for me."
The findings from your own research should carry the most weight. The articles on this website are personal opinion sprinkled with a few weak jokes.
I have not collaborated with any investigators in any research relating to bone marrow derived regenerative cell therapies. I gather my information from Pubmed and The Google and render my own opinion. My skepticism or optimism is irrelevant to the efforts of this or any company. Collaborations and licensing deals that companies may have with each other are their own responsibility; I only know what is publicly disseminated.
"2) Have you also written this message (broken link) I ask the question because your twitter account points to the username poorgradstudent . Are you suggesting that the trial is a giant bust?"
The Twitter handle is linked on this site. Apologies, but your other link did not work for me.
I only considered what was described in the C-Cure trial. I can not make extrapolations based on how different those results would be when repeated with another catheter. Similarly, I can not make extrapolations based on LVEF groupings.
I do not know what harvesting percentage is sufficient. My comment was simply based on the considerations one must make when reading an intent-to-treat analysis versus a per-protocol analysis.
Comments relating to this point can be heard on the webcast of the Investor’s Day presentation. They mention a delay due to interactions with the FDA, primarily relating to the trial endpoints. I accept this to be accurate. I do not have any conjecture to make about the choice of catheter in use, and do not know if or how that impacts their FDA interactions.
Since they require facilities to generate their cell-based therapy, I don’t consider the construction / establishment of these facilities to have any bearing on the prospects of their trials. I consider these facilities simply to be a necessity for their work.
Note: The excerpts from the email were edited for clarity, and names of individuals not employed by Cardio3 were removed. Also, a few spelling corrections were presumptively made.
Comments and questions welcome.